Booming Metabolic Sector Stocks: $ARDX, $ATXS, $CBAY, 1W +9.68% Growth
A Thematic Dive into the Metabolic Biotechnology Space
Theme Metabolic +9.68% - 1W change
Theme Metabolic - $ARDX $ATXS $CBAY $ICPT $MDGL $RYTM $VKTX
Swing Trader, Long Only: Growth Model (Diversified) Annualized Return + 13% and Swing Trader: Business Model (TA&FA) Annualized Return + 12%
The Metabolic Biotechnology Theme
In the biotechnology sector, certain companies focus on the development of pharmaceuticals aimed at treating gastrointestinal and metabolic disorders, earning them the classification of 'metabolic'. These companies, which include Ardelyx Inc., PhaseBio Pharmaceuticals Inc., and Catabasis Pharmaceuticals Inc., manufacture drugs aimed at mitigating and treating metabolic diseases and their associated symptoms.
This week, the metabolic theme has seen a promising performance, delivering a weekly change of +9.68%. This includes a mix of seven stocks, specifically $ARDX, $ATXS, $CBAY, $ICPT, $MDGL, $RYTM, and $VKTX.
The Financial Performance of Key Tickers
Ardelyx Inc. ($ARDX)
Ardelyx, a specialized biopharmaceutical company, made notable gains this week, with a significant price jump of +5.26% and another +6.06% surge, making it a top weekly gainer. Additionally, the volume of Ardelyx stock soared, breaking records with a daily growth of 278% of the 65-Day Volume Moving Average.
Catabasis Pharmaceuticals Inc. ($CBAY)
On the other hand, Catabasis Therapeutics didn't perform as well this week. Its stock price dipped by -6.5%, positioning it as the top weekly loser. While the downtrend is anticipated to continue, it's essential to watch for any possible changes in this trajectory.
Astria Therapeutics ($ATXS)
Astria Therapeutics has made headlines with a remarkable surge in volume. The company saw a daily growth of 1,377% and 342% of the 65-Day Volume Moving Average on two separate occasions. This significant volume increase suggests high investor interest and trading activity.
Overall Market Performance
The average market capitalization of the companies in the metabolic theme is around 1.3 billion dollars, with the highest valuation held by $MDGL at 3.8 billion and the lowest held by $ATXS at 251.1 million. The average weekly price growth across the group was 6.01%, while the average weekly volume growth was 60.13%.
As for the overall biotechnology industry, the average market capitalization is 2.2 billion dollars. The average weekly price growth across all stocks in the Biotechnology Industry was -1%, with the average weekly volume growth at 30.65%.
Industry Highlights
Biotechnology involves genetic or protein engineering to produce treatments and preventive therapies. The industry, which includes notable companies like Regeneron Pharmaceuticals, Moderna, and Incyte Corp, is heavily invested in research and development, striving to discover innovative health solutions.
The industry has witnessed some fluctuations with average weekly, monthly, and quarterly price growths of -1%, -1.65%, and 12.16% respectively. On the other hand, volume growth has been moderately stable, with weekly, monthly, and quarterly figures standing at 30.65%, -16.83%, and -2.55% respectively.
Fundamental Analysis Ratings
The metabolic theme has the following average fundamental analysis ratings: a Valuation Rating of 69, a P/E Growth Rating of 93, a Price Growth Rating of 45, and an SMR Rating of 97. The seasonality score is 40.
Meanwhile, the biotechnology industry displays a different set of ratings: a Valuation Rating of 50, a P/E Growth Rating of 87, a Price Growth Rating of 58, and an SMR Rating of 93. The seasonality score is neutral at 0.
Despite some market volatility, the metabolic theme within the biotechnology industry offers intriguing opportunities for investors. With the industry's emphasis on continual R&D, it is a space that is always worth watching for its potential to yield innovative, life-saving treatments, and correspondingly, rewarding investment returns.
Momentum Indicator for ATXS turns negative, indicating new downward trend
ATXS saw its Momentum Indicator move below the 0 level on March 25, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned negative. In of the 93 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for ATXS turned negative on March 28, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATXS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ATXS entered a downward trend on March 20, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ATXS advanced for three days, in of 272 cases, the price rose further within the following month. The odds of a continued upward trend are .
ATXS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.391) is normal, around the industry mean (13.458). P/E Ratio (0.000) is within average values for comparable stocks, (64.587). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.867). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (251.391).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ATXS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATXS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a developer of new medicines for the treatment of cardiovascular, metabolic and inflammatory diseases
Industry Biotechnology